MediWound (MDWD) Q2 FY26 earnings call

MediWound made significant strides in Q2 FY26, advancing its key pipeline asset EscharEx through Phase III enrollment and expanding its market potential. NexoBrid continued its strong commercial adoption in the U.S., bolstered by new government contracts and development initiatives. Despite a decline in Q2 revenue and increased R&D spend, the company reaffirmed its full-year revenue guidance, anticipating a strong second half driven by government-funded programs and development services.